What Has Been the Growth Trajectory of the Glaucoma Market?
The glaucoma market has seen considerable growth due to a variety of factors.
• In recent times, the glaucoma market size has seen significant growth. The size of the market is expected to expand from $7.76 billion in 2024 to $8.22 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%.
Reasons for the growth seen in the historic period include enhanced awareness about eye health, increased expenditure in healthcare, wider acceptance of telemedicine for eye care, growth in the healthcare infrastructure, and rises in government initiatives in healthcare.
What Can Be Expected from the Glaucoma Market in the Coming Years?
The glaucoma market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for glaucoma is anticipated to experience robust expansion in the forthcoming years, escalating to $10.20 billion in 2029 with a compound annual growth rate (CAGR) of 5.5%.
Factors contributing to this projected growth during the forecast period include an aging population, an increased incidence of glaucoma, heightened demand for less invasive surgeries, a rise in diabetes cases, and increasing hypertension rates. Key trends anticipated during this forecast period encompass advancements in diagnostic technologies, the introduction of novel drug therapies, technological progression in surgical devices, the offering of combination therapies, and the integration of robotic surgeries.
What Are the Critical Driver Fuelling the Glaucoma Market's Growth?
The escalating occurrence of long-term eye disorders is forecasted to drive the expansion of the glaucoma market. Chronic eye disorders are enduring conditions that impair sight and cause discomfort while necessitating continuous management or treatment. This rise in chronic eye issues comes as a result of aging populations, increased exposure to screens, lifestyle choices, and a higher incidence of illnesses such as diabetes and hypertension. Glaucoma treatment is needful for chronic eye illnesses to reduce intraocular pressure, avert further harm to the optic nerve, and maintain sight, as unattended glaucoma can result in irreversible blindness. For instance, the National Health Service (NHS), a publicly funded healthcare system in the UK, reported in December 2024 that over 2 million people in the UK suffer from sight loss in 2024. Furthermore, the figure of people with sight loss is expected to surge by 27%, hitting approximately 2.8 million by 2035. Therefore, the escalading occurrence of chronic eye conditions is propelling the glaucoma market.
How Are The Segments Defined Within The Global Glaucoma Market?
The glaucoma market covered in this report is segmented –
1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types
2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy
3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes
4) By Administration: Oral, Injections, Intravitreal, Other Administrations
5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma
3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma
Pre-Book The Glaucoma Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Glaucoma Market?
Key businesses in the glaucoma sector are channeling their efforts into creating unique therapies including Rho-kinase (ROCK) inhibitors. These inhibitors offer a dual-function solution, by both amplifying the aqueous humor outflow and relaxing trabecular meshwork cells, proving to be effective in glaucoma treatment. Rho-kinase (ROCK) inhibitors belong to a category of drugs aimed at disrupting the function of Rho-kinase enzymes responsible for cell contraction and are used in glaucoma treatment to decrease intraocular pressure. For example, in July 2023, the Japan-based Santen Pharmaceutical Co. Ltd., known for their eye care products, introduced Roclanda into the UK market. Roclanda, a fixed-dose composite of latanoprost and netarsudil, which is a unique Rho-kinase (ROCK) inhibitor, successfully lowers intraocular pressure by addressing trabecular meshwork malfunction. It is prescribed for adults with primary open-angle glaucoma or ocular hypertension who haven't seen sufficient IOP reduction with solo therapy using a prostaglandin or netarsudil. The Roclanda launch in Europe signifies the arrival of the first novel glaucoma drug class in a quarter of a century, marking a significant advancement in treatment. Combining netarsudil and latanoprost, Roclanda operates in synergy to boost outflow via both trabecular and uveoscleral paths, offering a wholistic solution to managing high IOP.
Who Are the Key Players in the Glaucoma Market?
Major companies operating in the glaucoma market are include:
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Teva Pharmaceuticals Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Bausch & Lomb Corp.
• Carl Zeiss Meditec
• Santen Pharmaceuticals Co. Ltd.
• Topcon Corporation
• Thea Laboratoires
• Corza Ophthalmology
• Lumenis Ltd.
• Alcon Inc.
• Viva BioInnovator
• Glaukos Corporation
• Iridex Corporation
• Nova Eye Medical Ltd.
• Renova Life Sciences Private Limited
• Qlaris Bio Inc.
• PolyActiva Pty Ltd.
• Nidek Co. Ltd.
• Haag-Streit AG
What Is The Most Dominant Region In The Glaucoma Market?
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
